腾盛博药-B(02137)：在《自然•医学》发表ENSURE II期研究结果

智通财经11-07

智通财经APP讯，腾盛博药-B(02137)发布公告，ENSURE II期研究结果已发表于同行评审期刊《自然•医学》。研究评估了siRNA药物elebsiran联合聚乙二醇干扰素α( PEG-IFNα)治疗方案的有效性和安全性，并将PEG-IFNα单药治疗方案作为对照组。此外，该研究还探讨了乙型肝炎病毒(HBV)治疗性疫苗BRII-179在识别免疫应答患者及提高乙肝表面抗原( HBsAg)清除率...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2581885516?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-07 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581885516","market":"sh","top_or_hot":-1,"title":"腾盛博药-B(02137)：在《自然•医学》发表ENSURE II期研究结果","media":"智通财经","content":"<div>\n<p>智通财经APP讯，腾盛博药-B(02137)发布公告，ENSURE II期研究结果已发表于同行评审期刊《自然•医学》。研究评估了siRNA药物elebsiran联合聚乙二醇干扰素α( PEG-IFNα)治疗方案的有效性和安全性，并将PEG-IFNα单药治疗方案作为对照组。此外，该研究还探讨了乙型肝炎病毒(HBV)治疗性疫苗BRII-179在识别免疫应答患者及提高乙肝表面抗原( HBsAg)清除率...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1366876.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>腾盛博药-B(02137)：在《自然•医学》发表ENSURE II期研究结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n腾盛博药-B(02137)：在《自然•医学》发表ENSURE II期研究结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-07 21:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1366876.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，腾盛博药-B(02137)发布公告，ENSURE II期研究结果已发表于同行评审期刊《自然•医学》。研究评估了siRNA药物elebsiran联合聚乙二醇干扰素α( PEG-IFNα)治疗方案的有效性和安全性，并将PEG-IFNα单药治疗方案作为对照组。此外，该研究还探讨了乙型肝炎病毒(HBV)治疗性疫苗BRII-179在识别免疫应答患者及提高乙肝表面抗原( HBsAg)清除率...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1366876.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02137","symbol_name":"腾盛博药-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1366876.html","article_id":"2581885516","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581885516","pubTimestamp":1762522594,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，腾盛博药-B 发布公告，ENSURE II期研究结果已发表于同行评审期刊《自然医学》。标题为《elebsiran和PEG-IFNα治疗慢性乙型肝炎感染：一项部分随机、开放标签的II期临床试验》的文章现已上线。ENSURE研究在病毒抑制的慢性HBV患者中分两部分进行。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02137":"腾盛博药-B","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股"},"translate_title":"Tengsheng Boyao-B (02137): Published ENSURE Phase II study results in Nature Medicine","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1.5},"content_text":"智通财经APP讯，腾盛博药-B(02137)发布公告，ENSURE II期研究结果已发表于同行评审期刊《自然•医学》。研究评估了siRNA药物elebsiran联合聚乙二醇干扰素α( PEG-IFNα)治疗方案的有效性和安全性，并将PEG-IFNα单药治疗方案作为对照组。此外，该研究还探讨了乙型肝炎病毒(HBV)治疗性疫苗BRII-179在识别免疫应答患者及提高乙肝表面抗原( HBsAg)清除率方面的潜在作用。标题为《elebsiran和PEG-IFNα治疗慢性乙型肝炎感染：一项部分随机、开放标签的II期临床试验》的文章现已上线。ENSURE研究在病毒抑制的慢性HBV患者中分两部分进行。在第一部分(队列 1-3)中，未接受过BRII-179给药的参与者被随机接受48周的PEG-IFNα单药治疗，或联合elebsiran治疗(每4周给药一次(Q4W)，剂量为200mg或100mg)。 在第二部分(队列4)中，在先前已完成的II期研究(BRII-179-835-001)中接受过9剂elebsiran联合BRII-179给药的参与者，根据乙肝表面抗体(“抗-HBs”)滴度峰值水平(分别为≥10 IU/L或<10 IU/L)被分类为BRII-179抗-HBs应答者或无应答者，随后在ENSURE研究中接受48周的elebsiran(100mg Q4W)联合每周一次的PEG-IFNα 治疗。ENSURE研究牵头主要研究者贾继东教授表示，“ENSURE研究旨在为慢性乙型肝炎的治愈性疗法提供亟需的科学依据并回答其中一些关键的科学问题。令人鼓舞的是，24周随访数据与治疗结束时的结果趋势一致，为elebsiran的额外临床获益提供了进一步支持，同时提示了BRII-179在激活慢性乙肝患者免疫并富集该人群以实现更高功能性治愈率方面的潜在新作用。我们期待在验证性研究中进一步确认这些发现。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581885516","isCrawlerRequest":true}